

NorthMiRs ШЦ ШЦ

NorthMiRs Inc.

Vision

To address the underlying immune dysregulation of sepsis using nanotechnology-enabled gene therapies.

Problem

Sepsis is an exaggerated, systemic immune response to an infection that often leads to multiple organ failure. Patients with sepsis-induced cardiac dysfunction experience high mortality rates, lengthy recovery times, and serious long-term effects.

Sepsis is the most common cause of death in critically ill patients and the most expensive reason for hospitalization.

The current standard of care for sepsis is inadequate. NorthMiRs aims to change this.

NorthMiRs Inc.

80 Saint George Street, Toronto ON, M5S 3H4 Canado Samantha.McWhirter@northmirs.com

NorthMiRs' team provides comprehensive expertise from benchtop to clinic.

NorthMiRs' therapeutic is the most effective and comprehensive solution because it uses unique microRNAs to regulate the immune response of the host.

Solution

From prior work in mesenchymal stem cell therapy for sepsis, NorthMiRs has determined the key components responsible for the therapeutic effects and refined them into a stable, synthetic, and scalable package.

miRNA regulates protein synthesis, some of which is associated with disease. NorthMiRs has identified specific miRNA whose levels are reduced in the hearts of septic patients. Lipid nanoparticle delivery of this specific miRNA ensures the efficacy of therapy. NorthMiRs' lead candidate, NM-001, has been shown to be anti-inflammatory, anti-microbial and protects organs from injury.

TREATING SEPSIS >> SAVING LIVES

NorthMiRs' lead candidate, NM-001, is using miRNA to heal the hearts of septic patients at risk of multi-organ failure.

Founding Team

Formulation experts



Gilbert Walker Expert in nanoparticle design



Samantha McWhirter CEO



Logan Zettle Formulation Scientist

Preclinical research experts



Claudia dos Santos Clinician-scientist expert



Amin Ektesabi Preclinical



Chirag Vaswani Preclinical Scientist